Resistance of Group B Streptococcus to Selected Antibiotics, Including Erythromycin and Clindamycin

Heelan, Judith S.; Hasenbein, Meredith E.; McAdam, Alexander J.

doi:10.1128/jcm.42.3.1263-1264.2004

Cited by 107 publications

(98 citation statements)

References 12 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…These increases are primarily seen among patients Ն15 years of age, as opposed to neonates or children. A number of reports have raised concerns regarding the increases in the numbers of erythromycin-resistant and/or clindamycin-resistant GBS isolates in North America and Europe (48)(49)(50)(51)(52). Resistance rates of over 20% for both erythromycin and clindamycin should preclude the use of these antibiotics in cases of iGBS.…”

Section: Cps Distributions and Incidence Ratesmentioning

confidence: 99%

Epidemiology of Invasive Group B Streptococcal Disease in Alberta, Canada, from 2003 to 2013

2016

View full text Add to dashboard Cite

bGroup B streptococci (GBS) cause severe invasive disease in both neonates and adults. Understanding the epidemiology of GBS provides information that can include determining disease prevalence rates in defined populations and geographic regions, documenting the success of GBS screening programs, and understanding antimicrobial susceptibility patterns. In Alberta, only neonatal invasive GBS (iGBS) disease is notifiable to health authorities. We performed a surveillance study of iGBS in Alberta, Canada, from 2003 to 2013. Over the 11-year period, the disease incidence rate increased from a low of 3.92 cases/100,000 population to a high of 5.99 cases/100,000 population. Clindamycin resistance also increased, from 12.2% to 32.5%. In summary, Alberta, Canada, has experienced an increase in GBS disease; the increase includes both neonatal and adult disease. CPS IV cases also notably increased during the surveillance period, as did resistance to erythromycin and clindamycin.

show abstract

Section: Cps Distributions and Incidence Ratesmentioning

confidence: 99%

Epidemiology of Invasive Group B Streptococcal Disease in Alberta, Canada, from 2003 to 2013

2016

View full text Add to dashboard Cite

show abstract

“…Among the subjects that were colonized with GBS, GBS colonization was higher among older women with age ≥30 years (12.79%) against 9.38% in younger (18)(19)(20)(21)(22)(23)(24)(25)(26)(27)(28)(29) women (Table 3). The difference was not statistically significant (X 2 = 0.426; P= 0.514).…”

Section: Resultsmentioning

confidence: 99%

“…One hundred and fifty (150) pregnant women participated in the study over a period of six months (May to December 2010). Their age range was 18-42 years with a mean of 30.25 (±4.65) and the age group in years was categorized as younger (18)(19)(20)(21)(22)(23)(24)(25)(26)(27)(28)(29) and older (≥30) pregnant women, which were 64 (42.7%) and 86 (57.3%) respectively. Table 1 shows parity and gestational age among other parameters as indicated.…”

Section: Resultsmentioning

confidence: 99%

Group B Streptococcus Carriage during Late Pregnancy in Ile-Ife, Nigeria

Onipede¹,

Adefusi²,

Adeyemi³

et al. 2012

Af J Clin Exp Micro

View full text Add to dashboard Cite

This study determined the prevalence of Group B Streptococcus (GBS) in late pregnancy and the antimicrobial susceptibility of isolated GBS as well as the impact of GBS infections on pregnancy related clinical outcome with a view of providing an epidemiological baseline data for policy formulation in the teaching hospital. It is an observational and cross-sectional hospital based study. One hundred and fifty pregnant women from 35-40 weeks of gestation were purposively selected and included in the study from May to December 2010. Vaginal swab samples were aseptically collected from the subjects after informed consent. The samples were assayed for presence of GBS. The susceptibility pattern of the isolated GBS to different antibiotics were assessed using disc diffusion and agar dilution techniques based on the Clinical and Laboratory Standards institute(CLSI) standards. The result showed prevalence of 11.3% GBS vaginal colonization which increased with age. There was no significant association between GBS colonization status and age (p >0.05)), gestational age (p >0.05)), gravidity (p >0.05) and obstetric risk factors (p >0.05)). There was no incidence of GBS infection observed. Although, all (17) the GBS isolates were 100% resistance to penicillin, ampicillin, cefoxitin and clindamycin. Resistance to cefotaxime (11.8%), erythromycin (64.7%) and vancomycin 70.6% were observed. Group B Streptococcus colonization in vagina in late pregnancy has been established in the antenatal clinic of the teaching hospital with the attendant risk to the fetus in the population of those affected. There were high and multiple resistance patterns of the GBS isolates to different antibiotics in this study. This calls for a review of the present hospital policy to include the routine screening of GBS during antenatal visits and surveillance.

show abstract

“…No clinical trial has evaluated the efficacy of non-beta-lactam regimens for IAP in women with serious penicillin allergy''. Moreover, resistance to clindamycin and erythromycin is increasing [4,42]. In a recent study of our group [43], the rate of resistance to clindamycin and erythromycin was 28 % and 30 %, respectively.…”

Section: Detection Of Gbs and Macrolide Resistance Genes By Pcrmentioning

confidence: 99%

Molecular-based Screening for Perinatal Group B Streptococcal Infection: Implications for Prevention and Therapy

2013

View full text Add to dashboard Cite

Group B streptococci (GBS) are a leading cause of infectious neonatal morbidity and mortality. Timely and accurate identification of colonized pregnant women is imperative to implement intrapartum antibioprophylaxis (IAP) to reduce the risk of early neonatal sepsis. Current guidelines recommend screening for GBS carriage with vaginal-rectal cultures. However, cultures require 24-72 h, thus precluding their use for intrapartum screening and these are only performed at 35-37 weeks gestation. New rapid molecular-based tests can detect GBS within hours. They have the potential to be used intrapartum and to allow for selective IAP in women carrying GBS. An advantage is that they can sometimes be performed by non-laboratory staff in the labor suite, thus avoiding delays in sample transfers to the microbiology laboratory. Another possible use of molecular-based assays is for the diagnosis of neonatal sepsis, where tests with a short turnaround time and high sensitivity and specificity are crucial. In this situation, the detection of microorganisms once antibiotic therapy has already been started is important, as treatment is started immediately once sepsis is suspected without waiting for microbiological confirmation. In this article, we discuss the state-of-the-art molecular-based tests available for GBS screening during pregnancy, as well as their implications for IAP for the diagnosis and prevention of neonatal sepsis.

show abstract

Resistance of Group B Streptococcus to Selected Antibiotics, Including Erythromycin and Clindamycin

Cited by 107 publications

References 12 publications

Epidemiology of Invasive Group B Streptococcal Disease in Alberta, Canada, from 2003 to 2013

Epidemiology of Invasive Group B Streptococcal Disease in Alberta, Canada, from 2003 to 2013

Group B Streptococcus Carriage during Late Pregnancy in Ile-Ife, Nigeria

Molecular-based Screening for Perinatal Group B Streptococcal Infection: Implications for Prevention and Therapy

Contact Info

Product

Resources

About